AI Overview: A recent headline suggested that a simple supplement may reverse heart disease. The research is interesting, but the real story is narrower. Tricaprin appears promising for a specific condition called triglyceride deposit cardiomyovasculopathy, or TGCV, where triglycerides accumulate inside heart and blood vessel cells because intracellular fat breakdown is impaired. That is not the same as saying a supplement reverses ordinary coronary artery disease. From a HormoneSynergy® longevity medicine perspective, this is a useful reminder that cardiovascular disease is biology, not branding.
The headline is understandable. A supplement that appears to improve heart disease sounds like the kind of story people want to believe. It is simple, hopeful, and easy to share. But cardiovascular disease is rarely simple, and this is exactly where longevity medicine has to slow the conversation down.
The supplement being discussed is tricaprin, also known as trisdecanoin. The condition being studied is triglyceride deposit cardiomyovasculopathy, or TGCV. TGCV is not the same thing as the usual coronary artery disease most people think about when they hear the phrase “heart disease.” It is a specific disorder in which triglycerides build up inside heart muscle cells and vascular cells because intracellular lipolysis, or fat breakdown inside the cell, appears to be impaired.
That distinction matters. In TGCV, tricaprin may help support a broken metabolic pathway. That is very different from saying the average person with coronary plaque, elevated ApoB, insulin resistance, high blood pressure, visceral fat, inflammation, poor sleep, or elevated Lp(a) can take a supplement and reverse heart disease.
What the study suggests
The early tricaprin research is genuinely interesting. Reports from Japanese researchers describe improvement in patients with TGCV, including people with difficult cardiovascular disease and impaired triglyceride processing inside cardiac tissue. More recent research has suggested improved survival in treated TGCV patients compared with matched controls.
That is worth studying. It may eventually become important for a subset of patients with unexplained heart failure, refractory angina, diabetes-associated cardiovascular disease, dialysis-related cardiovascular risk, or unusual lipid accumulation patterns. But it should not be turned into a general consumer message that “MCT oil reverses heart disease” or that supplements can replace evidence-based cardiovascular risk management.
The HormoneSynergy® perspective
At HormoneSynergy® Longevity Medicine, this kind of research is not dismissed. It is placed in context. The interesting part is not the supplement headline. The interesting part is that cardiovascular disease can involve multiple overlapping systems: lipoproteins, plaque biology, insulin resistance, inflammation, endothelial function, blood pressure, triglyceride handling, mitochondrial function, body composition, sleep, and genetic risk.
That is why a deeper cardiovascular strategy should not stop at a standard cholesterol panel. In the right clinical setting, it may include advanced cardiometabolic blood testing, ApoB, Lp(a), fasting insulin, triglycerides, inflammatory markers, blood pressure patterns, body composition, and imaging-based assessment of vascular structure and plaque burden.
This is also why Dr. Kathryn Retzler and HormoneSynergy® do not treat longevity medicine as a search for one missing supplement. Supplements may have a role. But they do not replace the foundational work of understanding the person’s actual physiology, risk pattern, metabolic health, vascular status, sleep, strength, body composition, and long-term trajectory.
What people should not take from this headline
The wrong takeaway is that tricaprin, MCT oil, coconut-derived fats, or any other supplement can be assumed to reverse ordinary heart disease. The current evidence is not broad enough to support that claim.
The better takeaway is that heart disease is not one disease. Some people may have hidden mechanisms that are missed by routine care. That does not mean everyone needs a new supplement. It means people need better context, better risk assessment, and a more complete understanding of what is actually driving their cardiovascular risk.
For most people, the highest-value cardiovascular work is still less glamorous: identifying plaque earlier, improving ApoB and LDL particle exposure when appropriate, addressing insulin resistance and triglycerides, reducing visceral fat, improving blood pressure, strengthening sleep and recovery, building muscle, and understanding risk before an event happens.
This is not a magic supplement story. It is a reminder that cardiovascular disease requires context. The question is not “What supplement fixes heart disease?” The better question is “What is actually driving this person’s cardiovascular risk?”
Related HormoneSynergy® resources
To understand this topic in a broader longevity medicine context, start with Preventive Cardiology and Longevity Medicine, Metabolic Health and Longevity Medicine, ApoB and Longevity, Triglycerides and Longevity, and Insulin Resistance Explained.
Frequently Asked Questions
Does tricaprin reverse heart disease?
Current research suggests tricaprin may help a specific condition called triglyceride deposit cardiomyovasculopathy, or TGCV. That is not the same as proving it reverses ordinary coronary artery disease in the general population.
Is TGCV the same as high triglycerides?
No. TGCV involves abnormal triglyceride accumulation inside heart and vascular cells due to impaired intracellular fat breakdown. High blood triglycerides are a common metabolic marker and may have different causes, including insulin resistance, alcohol intake, fatty liver, diet, medications, genetics, and thyroid dysfunction.
Should people take MCT oil or tricaprin for heart disease?
This should not be assumed from the current evidence. People with known or suspected cardiovascular disease should work with a qualified clinician and focus on the larger cardiovascular risk picture, including plaque burden, ApoB, Lp(a), blood pressure, metabolic health, inflammation, body composition, sleep, and fitness.
Why does this matter for longevity medicine?
It shows why cardiovascular disease should be evaluated through a systems lens. The goal is not to chase one supplement or one lab number, but to understand the biology driving risk and intervene earlier, more precisely, and more responsibly.